Call for Abstract

Scientific Program


    Warning: mysqli_query() expects at least 2 parameters, 1 given in /var/www/universal_code/pages/tracks.php on line 18

    Warning: mysqli_num_rows() expects parameter 1 to be mysqli_result, null given in /var/www/universal_code/pages/tracks.php on line 19
  • Abstract Submission
  • Register for Conference

World Congress on Biologics and Biosimilars, will be organized around the theme ““Advanced Research and Emerging Issues in the Field of Biologics and Biosimilars during COVID-19”.”

Biologics Meet 2021 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Biologics Meet 2021

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.


Biologics and Biosimilar analysis make the one among the foremost important aspect on the event on biological products. the utilization of production technologies like disposable and provide chain logistics can help companies such establish flexibility facility involved in biosimilar analytical methods.



Bio analytical methods include altogether global events of biosimilars for example: GMP protein analysis, pre-clinical and clinical program, Bioassay for comparability and potency testing.


  • Track 1-1High molecular weight species/aggregates
  • Track 1-2Establishing biosimilarity
  • Track 1-3High-order structures
  • Track 1-4Bioactivity (potency)
  • Track 2-1Avastin
  • Track 2-2Erbitux
  • Track 2-3Enbrel
  • Track 2-4Aranesp


For the event of biological calls many changes may occur. Concepts of biologics with considerations at initial stages, clinical developments are essential at early. For the successful development of biologics follow on proper scientific and strategic approaches are need. most likely , the drug safety factors and labelling requirements are the overcoming challenges and important in continue lately clinical steps. And now it's much required to develop a drug product in consistent with quality intentionally .


  • Track 3-1Biopharmaceuticals development.
  • Track 3-2Quality by Design for Biologics and Biosimilars.
  • Track 3-3Implimentation of the BPCI Act.
  • Track 3-4Advertising, promotion and labelling essentials.
  • Track 3-5Drug safety essentials.


biosimilars is likewise called as nonspecific adaptation of biosimilars. The clinically idle compound isn't withstanding with biosimilars but rather minor contrasts and profoundly like authorized item; additionally, there Presently a-days in pharmaceutical industry biosimilars is formed has another buzz. Furthermore, these are not any clinically important contrasts between the biologicals and therefore the reference item as far as intensity, wellbeing and immaculateness. The worldview of customary generics to biosimilars, and different parts of Biosimilar endorsements. Also, these Biosimilars 2019 will provides a phenomenal and overall chance to the researchers, accomplices and pharma pioneers from Biopharmaceutical and Biotechnology businesses to enhance and to research the key marketplace for Biosimilars and Biologics with an unmistakable photo of the executive approach for biosimilars and biologics. The US biosimilars, European biosimilars, Canada biosimilars, UK biosimilars take an interesting part in cross the world by 2019. Biosimilars development. And these biosimilar conferences will mainly specialise in bio similar development to deliver safe and successfully.


  • Track 4-1Need for a global pathway for biosimilars
  • Track 4-2Interchangeability or substitution of biosimilars
  • Track 4-3Opportunities for biosimilar development
  • Track 4-4Comparability for biosimilar development
  • Track 4-5Worldwide biosimilar development


Same proportion pharmacovigilance for biosimilars has comparatively more different from other products. Biosimilars 2019 session mainly look that have already been announced to incorporate enhanced tracking and follow-up of post marketing surveillance issues, and on FDA initiative planned different changes in AERS, pilots of latest developed post market strategies of drug-monitoring and ADR related problems. the rules of biosimilars for pharmacovigilance and pharma epidemiology are the points that shall be laid emphasis within the session In USA average annual income mostly spend on biologics comparing to generic drugs for example:16% on biologics and three on other drugs.


  • Track 5-1Evolving guidelines
  • Track 5-2Manufacturing methods
  • Track 5-3Product names
  • Track 5-4Generics and brand name products
  • Track 5-5Postapproval surveillance for immunogenicity


These Mainly discusses about differing types of medicine and adsorption distribution metabolism excretion pathways. And This biosimilars includes, In vitro diffusion cells for dissolution testing in formulation development, The preclinical testing of ADME in INVITRO. the first moto of this work was to suggest the biosimilars potential of biopharmaceutical arrangement which are known to extend the dissolution. These insoluble drugs which is orally absorbed. These Aims at addressing all such challenges of the pharma formulation sector at biologics and biosimilars at 2019 conference. The solubility includes in biopharmaceutical classification.


  • Track 6-1 Level A correlation
  • Track 6-2Level B correlation
  • Track 6-3Level C correlation
  • Track 6-4Multiple level C correlation
  • Track 6-5Level D correlation


These tracks mainly affect biosimilar meetings those that can attend by following biologics/protein/biosimilar product process science, New biosimilar development, portfolio Management, Reasearch&development, biosimilar market, business operations, scientific affairs. This track mainly discusses about Risk-sharing arrangement LATAM marketplace for bio-similar adopting innovative mechanism for generic drugs impact on global bio similar market and price and risk management.


  • Track 7-1Growth of Biological products
  • Track 7-2Developmental milestones
  • Track 7-3The patent cliff
  • Track 7-4Biosimilars market is highly fragmented
  • Track 7-5Biosimilar products
  • Track 8-1Analytical Comparisons
  • Track 8-2Preclinical & Clinical Studies
  • Track 8-3Extrapolation
  • Track 8-4Substitution & Interchangeability
  • Track 8-5Public Acceptance of Biosimilar Medicines


The active ingredient from the pharma product and its absorption into the circulation is especially specialise in equivalence release. Bioequivalence assessment includes strategies of topical dosage forms and bio equivalence approaches for transdermal dosage form and assessment of respiratory dosage form.

  • Track 9-1FUNDAMENTAL BIOEQUIVALENCE ASSUMPTION
  • Track 9-2CRITERIA FOR BIOEQUIVALENCE
  • Track 9-3STUDY DESIGN
  • Track 9-4CONDUCT OF BIOEQUIVALENCE TRIAL


The biological medical product may be a biosimilar manufactured by a special company by the copy of an ingenious product. the first biosimilar innovator products are officially approved biosimilar are often manufactured when the originally product patient expire. This session shall be highly useful for the biosimilar industry researchers to update themselves on the newest research updates from everywhere the planet . Not only these sessions and also there are some ways to seek out the precise place for all the biosimilar exhibitions related to present generation of biosimilars and biologics.


  • Track 10-1Biotechnology medicinal products for different drugs
  • Track 10-2Future of next generation biosimilars
  • Track 10-3Biotechnology medicinal products for different drugs
  • Track 10-4Biopharmaceuticals development
  • Track 10-5Future of next generation biosimilars


That any pharma product has successfully undergo the regulatory affairs scanners before launched within the market need less to say . Biosimilars and biologics are not any exceptions. the businesses developing these biosimilars and biologics aside from regulatory aspects tend to enjoy monopoly over their product. property Rights (IPR) and patents are ultimate tools to the biosimilar manufacturers for safeguarding their interests. 2016 was a record year for development of Biosimilars & biologics in US. during this year 16 IPR petition was filed. So, expected scenario of 2017 would be a boom in Biosimilar and biologics field.


  • Track 11-1The Budapest Treaty
  • Track 11-2The Patent Act and biological innovations
  • Track 11-3TRIPS negotiations on biotechnology


The negative tendency of biosimilars Brexit impact. The hindrance towards the value cutting approach taken by the NHS may be a major setback towards approval and launch of biosimilars in market. With Britain being among foremost clinical preliminary focuses is claimed to ascertain a diminishing within the eagerness of the manufacturers and specialists to try to to any longer preliminaries in Britain. Additionally, Brexit will cause the first rationale of British Biosimilars Association (BBA) to fall back-which went for expanding the use of Biosimilars.


  • Track 12-1No Tariffs or Quotas
  • Track 12-2Life Sciences Investment
  • Track 12-3The


Medication Delivery Companies and Market session is beginning to change for small , large, and medium scale pharmaceutical, Co biopharmaceutical Manufacturing and Industriesbland medications organizations, contract sedate conveyance organizations which may show from improvement to assembling. Tending to those dangers is a unprecedented test, due to the many-sided quality of the Clinical bio therapeutics themselves.


  • Track 13-1FORMULATION FORUM
  • Track 13-2OPEN INNOVATION PLATFORM
  • Track 13-3DRUG DEVELOPMENT EXECUTIVE
  • Track 13-4PRODUCT DEVELOPMENT STRATEGY


Biosimilars are a generally new subset of biopharmaceuticals, with the biotechnology business eventually developing to such an extent that off-patent nonexclusive compose items progressively will enter real markets. Up so far , quite 20 biosimilars for a group number of reference items are affirmed in realhttps://biologicsmeet.pharmaceuticalconferences.com/abstract-submission.php markets, principally the ecu Union. Just two items are formally endorsed as biosimilars within the us . The parent field of biopharmaceuticals itself keeps on displaying a poor supporting framework of knowledge assets. Those biopharmaceutical and biosimilar data assets that do exist for the foremost part are restricted in number, assorted variety, and advancement.


  • Track 14-1Drug safety of biosimilars products
  • Track 14-2Regulatory aspects
  • Track 14-3Regulatory affairs and IPR of biosimilars products
  • Track 15-1abatacept (Orencia)
  • Track 15-2abciximab
  • Track 15-3abobotulinumtoxinA
  • Track 15-4ado-trastuzumab emtansine